Ampicillin Sodium
| 證據等級: L5 | 預測適應症: 0 個 |
目錄
Ampicillin Sodium: No Repurposing Prediction Available
One-Sentence Summary
Ampicillin Sodium is a well-established broad-spectrum beta-lactam antibiotic, used globally to treat bacterial infections including pneumonia, meningitis, and urinary tract infections. The TxGNN model did not generate any repurposing predictions for this drug in this analysis run, and Ampicillin Sodium is not currently registered with SAHPRA. Until missing drug profile data are resolved and predictions are generated, no repurposing pathway can be evaluated.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Bacterial infections (broad-spectrum aminopenicillin antibiotic) |
| Predicted New Indication | None generated |
| TxGNN Prediction Score | Not available |
| Evidence Level | N/A — no predictions generated |
| South Africa Market Status | Not registered |
| Number of SAHPRA Registrations | 0 |
| Recommended Decision | Hold |
Why No Prediction Was Generated
Ampicillin Sodium is an aminopenicillin antibiotic whose mechanism centres on binding to penicillin-binding proteins (PBPs) in bacterial cell walls, inhibiting peptidoglycan cross-linking and ultimately causing cell lysis. This mechanism is highly specific to bacterial targets and does not directly map onto the host-disease pathways — oncological, immunological, or metabolic — that TxGNN most commonly identifies as repurposing opportunities.
The absence of predictions is likely compounded by missing input data. No DrugBank ID, no enumerated original indications, and no structured mechanism of action entry were available for this analysis run. The TxGNN pipeline depends on these fields to anchor the drug within the knowledge graph and compute meaningful disease-association scores; without them, the model cannot generate candidates.
There is a growing body of literature exploring indirect repurposing angles for beta-lactam antibiotics — for example, ceftriaxone’s glutamate-transporter upregulation in ALS research — but these findings relate to specific structural features of individual agents rather than to the penicillin core shared by Ampicillin. No analogous repurposing signal has been established for Ampicillin Sodium specifically, and the current evidence pack provides no basis to investigate such a direction.
Safety Considerations
Please refer to the SAHPRA-approved Professional Information (PI) for safety information. Report adverse drug reactions to SAHPRA via the MedSafety reporting system.
Conclusion and Next Steps
Decision: Hold
Rationale: The TxGNN model produced no repurposing predictions for Ampicillin Sodium, the drug carries no SAHPRA registrations, and the core input data required for a meaningful evaluation (DrugBank ID, structured MOA, approved indication text) are absent. There is no actionable repurposing signal to assess at this stage.
To proceed, the following is needed:
- Resolve DrugBank linkage: Query the DrugBank API to confirm or assign a DrugBank ID for Ampicillin Sodium and retrieve the structured MOA entry.
- Populate original indications: Retrieve the SAHPRA-approved Professional Information (PI) PDF for any registered Ampicillin Sodium product (including products registered under a combination or generic programme) and parse the approved indication text.
- Clarify registration status: Confirm whether Ampicillin Sodium (as a standalone product or as part of Ampicillin + Sulbactam combinations) has any active, suspended, or historically cancelled SAHPRA registration.
- Re-run TxGNN pipeline: Once the drug profile is complete, resubmit to the prediction pipeline to obtain scored repurposing candidates.
- Complete safety review: Retrieve key warnings, contraindications, and relevant drug–drug interaction data before any S1 safety screen can be performed.
⚠️ Disclaimer: This report is for research reference only and does not constitute medical advice. Any drug repurposing candidate must be validated through appropriate clinical investigation before clinical application.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.